Supernus Pharmaceuticals Inc

S49

Company Profile

  • Business description

    Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.

  • Contact

    9715 Key West Avenue
    RockvilleMD20850
    USA

    T: +1 301 838-2500

    E: [email protected]

    https://www.supernus.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - Specialty & Generic

    Fiscal Year End

    31 December 2026

    Employees

    778

Stocks News & Analysis

stocks

ASX utility share downgraded as electricity prices fall

Falling electricity prices weigh on earnings outlook for utility provider.
stocks

Chart of the Week: AI market leader is now surprisingly cheap

This AI beneficiary may still be one of the market’s most compelling bargains.
stocks

Weekly earnings wrap: Rio Tinto leads the way

A closer look at the key earnings results from the first week of August reporting.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,446.7036.800.39%
CAC 408,669.300.000.00%
DAX 4026,126.3076.05-0.29%
Dow JONES (US)54,349.12263.240.49%
FTSE 10010,888.308.920.08%
HKSE25,427.48488.34-1.88%
NASDAQ26,363.44221.55-0.83%
Nikkei 22565,662.41638.03-0.96%
NZX 50 Index13,958.0639.12-0.28%
S&P 5007,723.5512.97-0.17%
S&P/ASX 2009,265.0035.200.38%
SSE Composite Index3,875.073.36-0.09%

Market Movers